Document is current
Any future updates will be listed below
-
Authors
Reardon, Brendan https://orcid.org/0000-0002-1716-5720
Culhane, Aedin C. https://orcid.org/0000-0002-1395-9734
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
- License Information
-
More Information
Article History
Accepted: 14 November 2025
First Online: 2 January 2026
Competing interests
: B.R. has filed institutional patents on methods for clinical interpretation. E.M.V.A. has received research support (to institution) from Novartis, BMS, Sanofi and NextPoint. E.M.V.A. serves as a consultant or on scientific advisory boards of Novartis Institute for Biomedical Research, Serinus Bio and TracerBio. E.M.V.A. has equity in Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse and Tracer Bio. E.M.V.A. has received speaking fees from TD Cowen. E.M.V.A. has filed institutional patents on chromatin mutations and immunotherapy response and on methods for clinical interpretation, and has intermittent legal consulting on patents for Foley Hoag LLP. E.M.V.A. serves on the editorial board of Science Advances . A.C.C. declares no competing interests.
